SEC Filing Analysis: RECURSION PHARMACEUTICALS, INC. (RXRX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A C-level executive received a routine equity compensation package, consisting of Restricted Stock Units (RSUs) and stock options.
• Market Impact: Minimal. The grants represent a potential dilution of less than 0.1% of total shares outstanding.

Company Information

Field	Value
Company	RECURSION PHARMACEUTICALS, INC.
Ticker Symbol	RXRX
CIK	0001601830
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Khan Najat
CIK	0002020969
Title/Position	Chief R&D Commercial Officer
Relationship	Director, Officer

Transaction Details

This filing reports two grants: 84,925 RSUs and 169,851 stock options. The details below are for the RSU grant.

Field	Value
Form Type	4
Transaction Date	2025-11-05
Transaction Code	A (Grant)
Security Type	Class A Common Stock
Shares Involved	84,925
Price Per Share	$0.00
Total Value	$0
Shares Owned After	753,122
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0 (Grant)
% of Market Cap	0.00%
Total Shares Granted (RSUs + Options)	254,776
% of Shares Outstanding	0.06%
Post-Transaction Ownership (Direct)	753,122 shares (0.18% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: Recursion Pharmaceuticals has a market cap of $2.37 billion. The grant's notional value is a small fraction of this, and the dilutive impact is negligible.
• Dilution Impact: The combined grant of 254,776 potential shares (RSUs and options) represents approximately 0.06% of the 427.3 million shares outstanding. This is a very low level of dilution for existing shareholders.
• Transaction Significance: The transaction is a standard executive compensation award, not a market purchase or sale, and its size is immaterial relative to the company's public float and market capitalization.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Equity grants are routine, non-market transactions that are part of a pre-disclosed compensation structure. They do not signal new information about the company's immediate prospects.

Volume & Sentiment

• Expected Volume Impact: None. This is not an open-market transaction.
• Sentiment Indicator: Neutral. This is a standard course-of-business filing.

Additional Context

Transaction Notes

• Vesting Schedule: The RSUs vest quarterly over four years starting February 2026. The options vest monthly over four years starting December 2025. This long-term vesting schedule is designed to retain the executive and align their interests with long-term shareholder value.